Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in Russia

Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in Russia

A subset of patients (15 to 20%) with myasthenia gravis (MG) remains refractory to standard types of treatment. Analysis of efficiency of rituximab, a chimeric monoclonal antibody to surface antigen of B lymphocytes (CD20), in 16 patients suffering from refractory MG was performed. In all cases, the...

Full description

Bibliographic Details
Main Authors: N. I. Shcherbakova, N. A. Suponeva, V. V. Shvedkov, A. A. Shabalina, M. V. Kostyreva, V. A. Rudnichenko, O. I. Galkina
Format: Article
Language:Russian
Published: ABV-press 2015-09-01
Series:Nervno-Myšečnye Bolezni
Subjects:
refractory myasthenia
rituximab
selective b cell targeted therapy
b-cell depletion (cd20)
variations of autoantibodies to acetylcholine receptor (achr) levels
achr positive myasthenia gravis
qmg score
mgfa clinical classification
Online Access:https://nmb.abvpress.ru/jour/article/view/124

Similar Items

Similar Items